Driehaus Capital Management’s Ventyx Biosciences VTYX Stock Holding History

Driehaus Capital Management’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,107,631	Closed	-$38.5M	–	469
2023 Q3	$38.5M	Buy	1,107,631 +144,435	+15%	+$4.99M	0.5%	45
2023 Q2	$31.6M	Buy	963,196 +27,075	+3%	+$933K	0.4%	84
2023 Q1	$31.4M	Sell	936,121 -76,199	-8%	-$2.96M	0.44%	59
2022 Q4	$33.2M	Buy	1,012,320 +3,217	+0.3%	+$95.3K	0.49%	56
2022 Q3	$35.2M	Buy	1,009,103 +373,111	+59%	+$8.26M	0.53%	56
2022 Q2	$7.78M	Sell	635,992 -4,211	-0.7%	-$62.9K	0.13%	229
2022 Q1	$8.69M	Sell	640,203 -12,306	-2%	-$164K	0.11%	248
2021 Q4	$13M	Buy	+652,509	New	+$12.4M	0.13%	209

Other funds holding VTYX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Driehaus Capital Management's VTYX Position: Q4 2023 in Review

Driehaus Capital Management sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 1,107,631 shares — an estimated $38.5M sold.

Driehaus Capital Management first reported a position in VTYX in Q4 2021 and held it in 8 quarters. The position peaked at $38.5M in Q3 2023. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

Driehaus Capital Management reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
Driehaus Capital Management sold 1,107,631 Ventyx Biosciences shares in Q4 2023, an estimated $38.5M.
Driehaus Capital Management first reported a position in Ventyx Biosciences in Q4 2021 and held it in 8 quarters.
Driehaus Capital Management's Ventyx Biosciences position peaked at $38.5M in Q3 2023.
121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Driehaus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.